The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.
Cytena has developed a printer technology that allows single cell isolation for genomics research and clonal cell line development for biopharmaceutical production.
The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The deals follow a pair of other recent acquisitions by Precision for Medicine in the artificial intelligence technology and biomarker analysis fields.
The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.